DÄ internationalArchiveReferences

Review article

Treatment Strategies for Resistant Arterial Hypertension

Dtsch Arztebl Int 2011; 108(43): 725-31; DOI: 10.3238/arztebl.2011.0725

Mahfoud, F; Himmel, F; Ukena, C; Schunkert, H; Böhm, M; Weil, J

1. Lowel H, Meisinger C, Heier M, Hymer H, Alte D, Volzke H: Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies. Dtsch Med Wochenschr 2006; 131: 2586–91. MEDLINE
2. Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7. CrossRef MEDLINE
3. Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510–26. CrossRef MEDLINE
4.Deutsche Hochdruckliga e.V. – DHL: Leitlinien zur Behandlung der arteriellen Hypertonie. Nieren- und Hochdruckkrankheiten 2009; 38: 137–88.
5. Thoenes M, Tebbe U, Rosin L, et al.: Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists. Clin Res Cardiol 2011; 100(6): 483–91. CrossRef MEDLINE
6. Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP: Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003; 21: 1199–205. CrossRef MEDLINE
7. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H: Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27: 2332–41. CrossRef MEDLINE
8. Makris A, Seferou M, Papadopoulos DP: Resistant hypertension workup and approach to treatment. Int J Hypertens 2010; 2011: 598694. MEDLINE
9. Goncalves SC, Martinez D, Gus M, et al.: Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132: 1858–62. CrossRef MEDLINE
10. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131: 453–9. CrossRef MEDLINE
11. Douma S, Petidis K, Doumas M, et al.: Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921–6. CrossRef MEDLINE
12. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892–6. CrossRef MEDLINE
13. Hill MN, Miller NH, Degeest S: Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens 2011; 5: 56–63. CrossRef MEDLINE
14. Mahfoud F, Böhm M: Interventional renal sympathetic denervation – a new approach for patients with resistant hypertension. Dtsch Med Wochenschr 2010; 135: 2422–5. CrossRef MEDLINE
15. Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275–81. CrossRef MEDLINE
16. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932–4. CrossRef MEDLINE
17. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M: Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903–9. CrossRef MEDLINE
18. Symplicity HTN-1 Investigators: Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911–7. CrossRef MEDLINE
19. Lenartova M, Tak T: Iatrogenic pseudoaneurysm of femoral artery: case report and literature review. Clin Med Res 2003; 1: 243–7. CrossRef MEDLINE
20. Ukena C, Mahfoud F, Kindermann I, et al.: Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011; 58(11): 1176–82. CrossRef MEDLINE
21. Mahfoud F, Schlaich M, Kindermann I, et al.: Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940–6. CrossRef MEDLINE
22. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M: Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209–15. CrossRef MEDLINE
23. Heusser K, Tank J, Engeli S, et al.: Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619–26. CrossRef MEDLINE
24. Scheffers IJ, Kroon AA, Schmidli J, et al.: Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. Journal of the American College of Cardiology 2010; 56: 1254–8. CrossRef MEDLINE
25.Bisognano JD, Bakris G, Nadim MK et al.: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58(7): 765–73. CrossRef MEDLINE